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Introduction: The objective of this study was to investigate the possible role of UDP-glucose dehydrogenase (UGDH)
in osteoarthritis (OA) and uncover whether, furthermore how interleukin-1beta (IL-1β) affects UGDH gene expression.
Methods: UGDH specific siRNAs were applied to determine the role of UGDH in proteoglycan (PG) synthesis in
human articular chondrocytes. Protein levels of UGDH and Sp1 in human and rat OA cartilage were detected. Then,
human primary chondrocytes were treated with IL-1β to find out whether and how IL-1β could regulate the gene
expression of UGDH and its trans-regulators, that is Sp1, Sp3 and c-Krox. Finally, p38 mitogen-activated protein kinase
(MAPK) inhibitor SB203580 and stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) inhibitor SP600125
were used to pick out the pathway that mediated the IL-1β-modulated PGs synthesis and gene expression of
UGDH, Sp1, Sp3 and c-Krox.
Results: UGDH specific siRNAs markedly inhibited UGDH mRNA and protein expression, and thus led to an obvious
suppression of PGs synthesis in human articular chondrocytes. UGDH protein level in human and rat OA cartilage
were much lower than the corresponding controls and negatively correlated to the degree of OA. Decrease in Sp1
protein level was also observed in human and rat OA cartilage respectively. Meanwhile, IL-1β suppressed UGDH
gene expression in human articular chondrocytes in the late phase, which also modulated gene expression of Sp1,
Sp3 and c-Krox and increased both Sp3/Sp1 and c-Krox/Sp1 ratio. Moreover, the inhibition of SAP/JNK and p38 MAPK
pathways both resulted in an obvious attenuation of the IL-1β-induced suppression on the UGDH gene expression.
Conclusions: UGDH is essential in the PGs synthesis of articular chondrocytes, while the suppressed expression of
UGDH might probably be involved in advanced OA, partly due to the modulation of p38 MAPK and SAP/JNK
pathways and its trans-regulators by IL-1β.Introduction
Proteoglycans (PGs) are glycoconjugates composed of a
core protein backbone and numerous glycosaminoglycan
(GAG) side chains, which determine the fluid and electro-
lyte balance and the elasticity of articular cartilage and pro-
vide the living space for chondrocytes through interaction
with the collagen network. Thus, PGs are essential in* Correspondence: lbchen@whu.edu.cn; wanghui19@whu.edu.cn
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unless otherwise stated.maintaining cartilage homeostasis [1]. Loss of PGs would
lead to the imbalance of cartilage homeostasis, which fur-
ther accelerates the degeneration of cartilage matrix and
the apoptosis of chondrocytes, and finally triggers the
pathogenesis of osteoarthritis (OA), a chronic and degen-
erative arthritis with a high prevalence in the elderly [1,2].
UDP-glucose dehydrogenase (UGDH) catalyzes the
transformation of UDP-glucose to UDP-glucuronic acid, a
key precursor for the synthesis of the GAG chain in PGs
[3-6]. Stimulating UGDH enzyme activity with transform-
ing growth factor β (TGF-β) resulted in the enhanced
GAG synthesis in articular chondrocytes [7]. However,
whether UGDH is indispensable in the PG synthesis ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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volved in the pathogenesis of OA still remain unclear.
IL-1β is a key pro-inflammatory cytokine in the progres-
sion of OA, which attenuates the anabolism but enhances
the catabolism in the chondrocytes, through activating the
downstream signaling pathways, including those of stress-
activated protein kinase/c-Jun N-terminal kinase (SAP/
JNK) and p38 mitogen-activated protein kinase (p38
MAPK) [8-10]. It is well-known that IL-1β is one of the
key pro-inflammatory factors responsible for the PG loss
in OA pathogenesis. However, whether UGDH is involved
in the IL-1β-induced PG loss is unknown.
Specificity protein 1 (Sp1), Sp3 and Krueppel-related
zinc finger protein cKrox (c-Krox) are trans-regulators
sharing almost the same binding sites located in the pro-
moter region of UGDH gene [11,12]. Sp1 recognizes
GC- or GT-rich motifs and presents positive regulatory
effects on the transcriptional activity of the UGDH gene
[13,14]. Sp3 is another member of the Sp family, which
represses Sp1-mediated activation of gene transcription
due to the competition for their common binding sites
[12]. Meanwhile, c-Krox, the key trans-regulator of type
1 collagen [15], inhibits gene transcription of UGDH in
chondrocytes [11].
So, we hypothesized that UGDH is essential in the PG
synthesis of articular chondrocytes, and that IL-1β inhibits
UGDH gene expression through modulating UGDH trans-
regulators and the downstream signaling cascades, includ-
ing the SAP/JNK and p38 MAPK pathways, which might
be involved in the PGs loss of OA cartilage and contribute
to the OA pathogenesis. So, we detected PG content in hu-
man primary chondrocytes treated with UGDH-specific
siRNA, measured the protein level of UGDH and Sp1 in
human and rat OA cartilage and detected the influence of
the activation and inhibition of SAP/JNK or p38 MAPK
pathways on the gene expression of UGDH and its trans-
regulators in human articular chondrocytes, in an attempt
to uncover the role of UGDH in the PG synthesis of articu-
lar chondrocytes and the pathogenesis of OA.
Methods
Cartilage specimens
Human articular cartilage specimens from the knee joints
were obtained from OA patients diagnosed with advanced
OA using the criteria of the American College of Rheuma-
tology for OA undergoing total knee replacement surgery
(21 knees from 15 female patients, aged 66 ± 10 years)
with signed informed consent [16]. The procedures were
in accordance to the ethical guidelines of the Helsinki
Declaration of 1975 (as revised in 2000) and approved by
Medical Ethics Committee of the Zhongnan Hospital of
Wuhan University (number 2012030). Microscopically
normal cartilage (MNC) and degenerative cartilage (DC)
from the same patient was collected respectively from thetibial plateau using a surgical microscope with 8-fold amp-
lification, paired and numbered [17].
Pathogen-free adult Wistar rats (weight 220 to 280 g)
were supplied by Experimental Centre of Medical Scien-
tific Academy of Hubei province, which also approved
the animal study protocol applied in the study (number
2008–0005). The protocol was in accordance with the
Guide for the Care and Use of Laboratory Animals
(eighth edition) by the National Research Council of the
United States National Academies. The animal study
was performed in the Animal Biosafety Level-3 Labora-
tory of Wuhan University (Wuhan, China) accredited by
the Association for Assessment and Accreditation of La-
boratory Animal Care International (AAALAC). The
OA model was induced as described previously [18]. Six-
teen rats were grouped into the control group and the
OA group, which were intra-articularly injected respect-
ively with 20 μL of sterile 0.9% saline or 4% (w/v) papain
(Sigma-Aldrich, MO, USA) solution in saline to the right
knees of the rats on days 1, 4 and 7. Two weeks after
the last injection, all the rats were sacrificed under
anesthesia for the knee joints.
Histopathology assay
Cartilage samples from the weight-bearing area of the
knee joint were used in pathological testing. Human MNC
samples were defined as the control, while the DC samples
were defined as the OA cartilage. Samples of human and
rat cartilage were fixed in 4% paraformaldehyde overnight
and embedded in paraffin wax, successively. Then, sec-
tions of 5 μm were obtained perpendicularly to the surface
of articular cartilage. HE and Safranin O staining was per-
formed according to the standard protocol. The degree of
OA was presented independently by three observers ac-
cording to the modified Mankin scoring system using a
blinded method [19]. Moreover, protein expression of
UGDH and Sp1 in the chondrocytes was also detected
using immunohistochemical (IHC) assay with anti-UGDH
(1:150, Proteintech, Chicago, IL, USA) and anti-Sp1
(1:150, Proteintech) antibodies. The relative protein level
of UGDH and Sp1 was presented as the mean absorbance
of each positively stained chondrocyte using NIS-elements
software (Nikon, Tokyo, Japan).
Chondrocyte isolation, culture and treatment
Human cartilage samples without microscopically visible
degeneration were dissected and digested with 0.25%
trypsin (Sigma-Aldrich, MO, USA) for 30 minutes and
0.2% collagenase typeII (Sigma-Aldrich) for 12 h in
serum-free DMEM/F-12 (1:1 v/v) (Thermo Fisher, Beijing,
China). Then, chondrocytes were collected and cultured
as a monolayer in DMEM/F12 (1:1 v/v) with 10% (v/v)
fetal bovine serum (Thermo Fisher), 100 IU/mL penicillin
(Biyotime, Haimen, China), 100 μg/mL streptomycin (Biyotime),
Table 2 The primers used in the study
Target
genes
Gene ID Sequence Annealing (°C) Product
size (bp)
UGDH 2582 F: 5′-CAGGCTATGT
TGGAGGACCC-3′
60 162
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Hereafter, the chondrocytes were treated with UGDH-
specific siRNA for 4 h using Lipofectamine 2000 Reagent
(Life technologies, Grand Island, NY, USA) and cultured
for another 48 h following the manufacturer’s protocol.
Details of the UGDH-specific siRNA are listed in Table 1.
Chondrocytes were also treated with human recombinant
IL-1β (10, 20, 40 ng/mL, PeproTech, Rocky Hill, NJ, USA)
for 12, 24 and 48 h, and were also pretreated with p38
MAPK inhibitor SB203580 (20 μM, Sigma-Aldrich) or
SAP/JNK inhibitor SP600125 (10 μM, Sigma-Aldrich) for
0.5 h and subsequently co-treated with 10 ng/mL IL-1β
for another 48 h, to detect the mRNA and protein level of
the genes of interest. Meanwhile, chondrocytes were also
treated with IL-1β (10 ng/mL) for 0 to 120 minutes or pre-
treated with SP600125 or SB203580 for 30 miutes and
then treated with 10 ng/mL IL-1β for another 30 minutes
for the phosphorylation status of JNK and p38 MAPK.
Chondrocytes from at least three individuals were applied
in every in vitro experiment.
GAG detection
GAG content was detected using 1,9-dimethylmethylene
blue (DMB, Sigma-Aldrich) reagent as reported [20-22].
Absorbance at 570 nm was measured using a UV-1601
spectrophotometer (Shimadzu, Kyoto, Japan). A standard
curve constructed with chondroitin sulfate sodium salt
from shark cartilage (Sigma-Aldrich) was used to quantify
GAG content in the chondrocyte cultures. Then, total
GAG was determined as GAG content versus protein con-
tent of the same culture. Meanwhile, chondrocytes were
cultured on coverslips, fixed in 10% (w/v) neutral formalin
for 15 minutes, stained with 0.5% (w/v) Alcian blue dye
and photographed using an AZ100 Microscopes (Nikon,Table 1 The small interfering RNA applied in the study
Target genes Gene ID siRNA pairs Sequence
















UGDH, UDP-glucose dehydrogenase; NA, not applicable.Tokyo, Japan). Relative GAG content was determined as
mean absorbance of each positively stained chondrocyte.
Real-time quantitative PCR assay
Real-time quantitative PCR assay was performed as pre-
viously described [23]. Total RNA was isolated using
TRIzol reagent (Life Technologies). Single-strand cDNA
was obtained using a First Strand cDNA Synthesis Kit
(Takara, Dalian, China). Primer Premier 5.0 (Premier
Biosoft, Palo Alto, CA, USA) and the NCBI BLAST data-
base were applied to design the primers for the genes of
interest. The primers used in this study are listed in
Table 2. The RT-PCR assay was performed on a StepOne
thermal cycler (Applied Biosystems, Grand Island, NY,
USA) using reverse-transcription (RT)-PCR kits (Takara)
using the following procedure: pre-denaturation at 95°C
for 30 sec, denaturation at 95°C for 5 sec, annealing at Tm
for 30 sec, and extension at 72°C for 30 sec. The last three
steps ran for 40 cycles. Relative standard curves were con-
structed for relative quantification. The expression of all
the target genes was normalized to the GAPDH gene to
standardize comparison.
Western blotting assay
Total proteins were obtained from human cartilage sam-
ples and chondrocyte cultures using radioimmunoprecipi-
tation assay (RIPA) lysis buffer (Biyotime), while nuclear
proteins were extracted using a nuclear protein extraction
kit (Biyotime). Then, proteins were size-fractionated byR: 5′-TCGACAGGA
TTCTACCACTTCTT-3′




















UGDH, UDP-glucose dehydrogenase; Sp1, specificity protein 1; Sp3, specificity
protein 3; c-Krox, krueppel-related zinc finger protein cKrox; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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(Millipore, Bellerica, MA, USA). The target proteins were
probed with anti-UGDH (1:1,000, Proteintech), anti-Sp1
(1:800, Proteintech), anti-Phospho-SAPK/JNK (Tyr185)
(1:500, Enogene, Nanjing, China), anti-Phospho-p38 MAPK
(Thr180) (1:500, Enogene), anti-SAPK/JNK (1:1000, Sangon,
Shanghai, China), anti-p38 MAPK (1:1000, Sangon),
anti-GAPDH (1:1,000, Proteintech) and anti-lamin A/C
(1:1,000, Proteintech) primary antibodies, incubated with
horseradish peroxidase-conjugated secondary antibody
(1:5,000, Proteintech). Blots were developed using ECL re-
agent (Advansta, Menlo Park CA, USA). A Fusion FX sys-
tem (Vilber Lourmat, Marne-la-Vallée, France) was applied
to photograph the blots. Then, relative the protein level of
UGDH and SP1 was obtained using Quantity One software
(Version 4.6, Bio-Rad, Berkeley, CA, USA), compared with
the corresponding controls and standardized to GAPDH.
Statistical analysis
Data analysis was performed using SPSS 17.0 (SPSS
Science Inc., Armonk, NY, USA) and Prism 5.0 (GraphPad
Software, San Diego, CA, USA). Results were presented as
mean ± standard error of the mean (SEM). One-way analysisFigure 1 UDP-glucose dehydrogenase (UGDH)-specific siRNA suppres
chondrocytes. Human articular chondrocytes were treated with UGDH-spe
detected using real-time PCR (A) and western blotting assay (B, C), while G
1,9-dimethylmethylene blue dye (D) and Alcian blue dye (E, F). The protein
using Quantity One software (Version 4.6, Bio-Rad). Values are presented as
experiments. *P <0.05 and **P <0.01 versus control.of variance (ANOVA) or Student’s t-test, as appropriate,
after testing the homogeneity of variances, were performed
to analyze the data. The Wilcoxon rank-sum test was
applied to analyze the difference between Mankin scores for
cartilage from the control and the OA group. Spearman
rank correlation analysis was performed to test the correl-
ation between Mankin score and UGDH protein level in
human and rat cartilage. Values of P <0.05 were considered
statistically significant.
Results
UGDH was essential in PG synthesis of human articular
chondrocytes
Obvious decreases in UGDH mRNA and protein levels
were observed in human articular chondrocytes treated
with three different UGDH-specific siRNA (Figure 1A, B
and C, P <0.05), which was accompanied by a decrease in
total GAG content in the chondrocyte cultures (Figure 1D,
P <0.05). Meanwhile, the staining of chondrocytes treated
with UGDH-specific siRNA by Alcian blue was much
lower than the control (Figure 1E and F, P <0.05), which
also indicated the suppression of PG synthesis in the
chondrocytes due to inhibited UGDH gene expression.sed glycosaminoglycan (GAG) synthesis in human articular
cific siRNA for 48 h. Then, mRNA and the protein level of UGDH were
AG content of these chondrocyte cultures were detected with
level of UGDH was presented as gray level of the blots quantified
mean ± standard error of the mean from at least three independent
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Serious degenerative features of human OA cartilage,
namely extensive surface irregularities, clefts to calcified
zone, and even complete disorganization, were observed
using HE staining (Figure 2A and B). A marked decrease
in GAG content was observed in DC by safranin O
staining, when compared with MNC from the same OA
patient (Figure 2E and F). Mankin scores of MNC were
also much lower than those for DC (P <0.05), while the
UGDH protein level of DC was also significantly lower
than that of MNC (P <0.05). An additional figure file
shows this in more detail (see Additional file 1A). Simi-
lar degenerative features were also observed in rat OA
cartilage, together with an increase of chondrocyte num-
bers (Figure 2C and D). Safranin O staining of rat OA car-
tilage was also much lighter (Figure 2G and H). Moreover,
Mankin scores for rat OA cartilage were much higher
(P <0.05), while UGDH protein level was also lower when
compared with normal control (P <0.05). An additionalFigure 2 Histopathology assay of human and rat osteoarthritis (OA) c
collected, and the rat OA model was induced. Human OA cartilage was div
cartilage (DC). The former was defined as the control, and the latter as OA car
UDP-glucose dehydrogenase (UGDH) protein level was detected using immu
of each chondrocytes using NIS-Elements software (Nikon, Tokyo, Japan), and
OA. Cartilage samples from 11 knees were included in the pathological analys
of human and rat cartilage (M, N) was performed. Scale bars, 100 μm.figure file shows this in more detail (see Additional file 1B).
Further correlation analysis showed that UGDH protein
level in both human and rat cartilage was negatively corre-
lated with the Mankin score (P <0.05, Figure 2M and N),
which indicated a strong correlation between the sup-
pressed UGDH protein level with the stimulated cartilage
degeneration during OA.
IL-1β decreased UGDH gene expression and inhibited
GAG synthesis
To determine whether IL-1β was involved in the suppres-
sion of UGDH protein expression in OA cartilage, we
treated human articular chondrocytes with recombinant
IL-1β and found that IL-1β decreased the total GAG con-
tent of chondrocyte cultures in a concentration- and time-
dependent manner (all P <0.05, Figure 3A). Although
mRNA level of UGDH was increased after 12 h, IL-1β
downregulated UGDH mRNA level in a concentration-
dependent manner after 24 h or 48 h of treatment (P <0.05,artilage. Human cartilage from the tibial plateau of OA patients was
ided as microscopically normal cartilage (MNC) and degenerative
tilage. HE staining (A-D) and Safranin O staining (E-H) was performed.
nohistochemical (IHC) assay (I, L) and presented as mean optical density
the modified Mankin score system was applied to grade the degree of
is. Then, correlation between the Mankin score and UGDH protein level
Figure 3 Interleukin 1β (IL-1β) modulated glycosaminoglycan (GAG) synthesis and UDP-glucose dehydrogenase (UGDH) gene
expression. Human articular chondrocytes were treated with recombinant IL-1β for 12 h, 24 h and 48 h. Then, GAG content (A) and the mRNA
level of UGDH (B) of chondrocyte cultures was detected. Meanwhile, UGDH protein level from chondrocytes treated with IL-1β for 48 h was de-
tected using western blotting assay (C, D). Values were presented as mean ± standard error of the mean from at least three independent experi-
ments. *P <0.05 and **P <0.01 versus control.
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tein level was downregulated by IL-1β treatment for 48 h
(all P <0.05, Figure 3C and D).
Transcriptional regulation of UGDH
Sp1, Sp3 and c-Krox are the key trans-regulators of the
UGDH gene [11-13]. Here, Sp1 protein level in human
DC was markedly lower than the MNC of the same pa-
tient (P <0.05, Figure 4A and B). Meanwhile, a notable
decrease of Sp1 protein level in OA rat cartilage was also
observed (P <0.05, Figure 4A and B). Moreover, the
mRNA expression of Sp1 in human primary chondro-
cytes was downregulated after IL-1β treatment, while
c-Krox mRNA levels were increased (P <0.05, Figure 4C
and E). Sp3 mRNA expression was stimulated by IL-1β
after 12-h and 24-h treatment, while an obvious decrease
in Sp3 mRNA level was detected after 48 h (P <0.05,
Figure 4D). A concentration-dependent suppression of
protein expression and nuclear translocation of Sp1 were
also observed in chondrocytes treated with IL-1β for
48 h (all P <0.05, Figure 4F and G). Moreover, the ratio
of Sp3/Sp1 and c-Krox/Sp1 was markedly increased after
IL-1β treatment (P <0.05). An additional figure file
shows this in more detail (see Additional file 2).
IL-1β modulated the expression of UGDH through the
p38 MAPK and SAP/JNK pathway
IL-1β obviously increased the phosphorylation levels of
both SAP/JNK and p38 MAPK from 5 minutes to 1 h,
or even longer in human articular chondrocytes, whilethe peak of phosphorylation last from 15 to 60 minutes
(Figure 5A). Then, the phosphorylation status of both
SAP/JNK and p38 MAPK started to fade after 60 minutes
(Figure 5A). However, the activation of phosphorylation
of SAP/JNK and p38 MAPK by IL-1β were obviously re-
duced by the pretreated SP600125 and SB203580, re-
spectively (Figure 5B). Further, SB203580 promoted
GAG synthesis and UGDH mRNA expression but did
not affect the trans-regulators, while SP600125 affected
none of these process (P <0.05, Figure 6A-D). However,
IL-1β inhibited GAG synthesis and gene expression of
UGDH, Sp1 and Sp3, but stimulated c-Krox gene expres-
sion (P <0.05, Figure 6A-D), while both SB203580 and
SP600125 attenuated the effect of IL-1β on these process
(P <0.05, Figure 6A-D), which indicated that both p38
MAPK pathway and SAP/JNK pathway were involved in
the IL-1β-modulated UGDH gene expression.
Discussion
It is well-known that the content of PG is most abun-
dant in the mid-zone of articular cartilage, rather than
the superficial or deep zones; chondrocytes in the mid-
zone highly synthesize both PGs and collagens, while
chondrocytes in the superficial and deep zones mainly
synthesize collagens (type II and type X, respectively) in-
stead of PG [24]. Meanwhile, chondrocytes in the mid-
zone but not the superficial or deep zones of articular
cartilage have high UGDH activity [25], which indicates
a possible correlation between UGDH enzyme activity
and PG synthesis in articular chondrocytes. Moreover,
Figure 4 Gene expressions of trans-regulators of UDP-glucose dehydrogenase (UGDH). Specificity protein 1 (Sp1) protein level in was
detected in both human and rat cartilage samples (A, B). Relative mRNA levels of Sp1, Sp3 and Krueppel-related zinc finger protein c-Krox (c-Krox)
were also detected in human primary chondrocyte treat with IL-1β (C-E). Total and nuclear Sp1 protein level was also detected and quantified
(F, G). MNC, microscopically normal cartilage; DC, degenerative cartilage. Scale bars, 100 μm. Values are presented as mean ± standard error of the
mean from at least three independent experiments. *P <0.05 and **P <0.01 versus control.
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nan synthesis in prostate cancer cells, which thus pro-
motes the metastasis progression of the cancer cells
[26], while the stimulated UGDH expression by TGF-β
promotes hyaluronan production in articular surface
cells in chicks [6,7]. In the present study, suppressing
UGDH gene expression led to an obvious decrease in
PG synthesis in human articular chondrocytes. Taken to-
gether, these findings suggest that UGDH plays a critical
role in the PG synthesis of articular chondrocytes, al-
though the intracellular synthesis of UDP-glucuronic
acid was not measured in the present study. As PG are
the key components in the cartilage matrix, which main-
tain the fluid and electrolyte balance, and provide the
living space of chondrocytes and the elasticity of the car-
tilage, we speculate that UGDH might further be an es-
sential player in maintaining cartilage homeostasis.
As a typical degenerative disease of articular cartilage,
OA starts with the disturbance of cartilage homeostasis,which leads to the subsequent loss of cartilage matrix
and disorganization of articular cartilage. However, no
correlation between the PGs loss and UGDH in OA has
been reported, except Zemel et al. who indicated that no
significant increase in UGDH activity was observed be-
tween human normal and OA chondrocytes, and that
the lack of significantly enhanced UGDH activity could
contribute to continuous GAG loss during OA progress
[27]. In the present study, we found, for the first time,
that protein level of UGDH is obviously lower in DC
than that of MNC from the same OA patient, while
chondrocytes also expressed less UGDH protein in rat
OA cartilage than that of the normal cartilage. Taken to-
gether, the suppressed protein expression and the un-
changed enzyme activity of UGDH help to explain the
inability of chondrocytes to handle the continuous GAG
loss in the advanced OA. However, the OA cartilage
samples from either the OA patients undergoing total
knee replacement or the rats with papain-induced OA,
Figure 5 Phosphorylation of stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) and p38 mitogen-activated protein
kinase (MAPK) protein in human primary chondrocytes. Human primary chondrocytes were treated with IL-1β treatment (10 ng/mL) for 0 to
120 mintes (A) or pretreated with SP600125 or SB203580 for 30 minutes and then treated with 10 ng/mL IL-1β for 30 minutes (B). Then, phosphorylated
and total protein level of SAP/JNK and p38 MAPK, as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein level, were detected using
western blotting assay. IC, IL-1β control, namely chondrocytes treated with 10 ng/mL IL-1β for 30 minutes; ISP, chondrocytes pretreated with
SP600125 for 30 minutes and subsequently co-treated with the SP600125 and 10 ng/mL IL-1β for another 30 minutes; ISB, chondrocytes
pretreated with SB203580 for 30 minutes and then co-treated with the SB203580 and 10 ng/mL IL-1β for another 30 minutes.
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the joints and a rapid progress to the terminal stage of
OA, were all at their advanced stages, which could not
fully replicate the natural pathogenesis of OA dynamically.
Other milder models with a more natural and mimic
process, like the aging model and running model etc.,
would be better for the investigation in the role of UGDH
in OA. Meanwhile, how the expression of UGDH was sup-
pressed in articular chondrocytes still remained unclear.
IL-1β is one of the major pro-inflammatory factors
highly expressed in cartilage and synovium throughout
the OA pathogenesis and responsible for the PGs loss
and cartilage degeneration [8,9,28-30]. However, Maneix
et al. reported that exogenous IL-1β failed to modulate
UGDH enzyme activity in articular chondrocytes [7],
while Hickery et al. also found that IL-1α, another mem-
ber of the IL-1 family, could neither modulate UGDH
activity [25]. In the present study, we observed that UGDH
gene expression was stimulated by IL-1β (10 ng/ml) after
a 12-hour exposure, which was in accordance with the re-
sults from Maneix et al. [7], while obvious inhibitions of
UGDH gene expression were observed after IL-1β treat-
ment at higher concentrations or for longer time, which
thus resulted in the suppressed synthesis of GAG in the
chondrocytes. All these findings indicated that IL-1β
might possibly be involed in the suppression of UGDH
protein expression in OA cartilage, and that the restricted
UGDH expression induced by IL-1β, rather than thenegligible alteration of UGDH enzyme activity, that might
participate in the compensation and decompensation of
cartilage matrix during OA pathogenesis. However, as IL-
1β presents plentiful effects on cartilage, the functional
measurement of IL-1β on GAG-precursor synthesis would
further strengthen the evidence in the present study.
Meanwhile, as there are multiple factors involved in OA
pathogenesis, other stimuli including 17β-oestradiol, TGF-
β and IGF-1 could also be involved in this process through
modulate either the enzyme activity or gene expression of
UGDH [6,7,13,25]. Combining the evidences that UGDH
plays an essential role in GAG synthesis and cartilage
homeostasis, we suggest that UGDH might be possibly a
novel target for OA therapy.
Previous studies have demonstrated that IL-1β acts
through the activation of downstream signaling cascades.
IL-1β binds to type 1 IL-1 receptor (IL-1R1) and then
triggers the downstream cascade reaction, which finally
leads to the activation of the SAP/JNK, p38 MAPK and
NF-κB signaling pathways [10,31,32]. However, although
all the three pathways are involved in the metabolic dis-
turbance induced by IL-1β, NF-κB signaling is believed
to be mainly responsible for the inflammatory activity of
IL-1β. Meanwhile, recent data suggests that it the SAP/JNK
and p38 signaling pathway mediatesd the IL-1β-induced
suppression of xylosyltransferase I gene expression and the
subsequent GAG synthesis in human articular chondro-
cytes [33]. In the present study, we also observed that
Figure 6 IL-1β, SB203580 and SP600125 modulated UDP-glucose dehydrogenase (UGDH) gene expression. Human articular chondrocytes
were pretreated with SB203580 (20 μM) and SP600125 (10 μM) for 30 minutes and/or subsequently treated with IL-1β (10 ng/mL) for another
48 h. Total GAG (A), the mRNA level of UGDH, specificity protein 1 (Sp1), Sp3 and Krueppel-related zinc finger protein c-Krox (c-Krox) (B), and
the protein level of UGDH and Sp1 (C, D) was also detected. Values are presented as mean ± standard error of the mean from at least three
independent experiments. *P <0.05, **P <0.01 versus control, #P <0.05, ##P <0.01 versus the IL-1β group.
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attenuation of the IL-1β-induced suppression of the gene
expression of UGDH and its trans-regulators; this indicates
that IL-1β could suppress UGDH gene expression and con-
sequently inhibit PG synthesis in articular chondrocytes,
which might suppress matrix restoration and contribute to
the OA progression.
Sp1 binds to the GC or GT rich motifs of UGDH pro-
moter sequence and promote transcriptional activity of
UGDH gene, while Sp3 and c-Krox were suggested to be
playing the negative regulatory roles [11-13]. Inhibition
of Sp1 expression with siRNA resulted in attenuation of
UGDH enzyme activity, reduction of UGDH gene pro-
moter activity and consequent depression of UGDH
mRNA levels [13]. Meanwhile, TGF-β stimulated UGDH
gene expression through increasing DNA binding of Sp1
to the sequences located in UGDH promoter [13]. It was
also reported that IL-1β inhibited COL2A1 gene tran-
scription by increasing the Sp3/Sp1 ratio and inhibitingthe binding of Sp1 and Sp3 to the promoter [34]. Bind-
ing to the same sequence that binds Sp1 and Sp3,
c-Krox was suggested to act in concert with Sp1 and
Sp3 to modulate UGDH gene expression [11]. Overex-
pression of c-Krox gene in rabbit articular chondrocytes
leads to marked decrease in mRNA and protein level of
UGDH gene, which is mediated by the increased binding
of c-Krox to the cis-sequence located in the UGDH pro-
moter [11]. In the present study, IL-1β altered the gene
expression of Sp1, Sp3 and c-Krox, decreased the nuclear
translocation of Sp1 protein, and increased the Sp3/Sp1
ratio, as well as c-Krox/Sp1 ratio. Altogether, it suggests
that Sp1, Sp3 and c-Krox mediated the modulation of
IL-1β on UGDH gene expression. Sp3/Sp1 ratio and c-
Krox/Sp1 ratio in chondrocytes might be helpful in esti-
mating the effects of drugs, cytokines or growth factors
on cartilage homeostasis. Moreover, decreasing Sp3/Sp1
and c-Krox/Sp1 ratio could help to restore the cartilage
phenotype in osteoarthritic joints.
Wen et al. Arthritis Research & Therapy  (2014) 16:484 Page 10 of 11Conclusions
In conclusion, UGDH plays a critical role in the PG syn-
thesis of articular chondrocytes, of which the expression
is suppressed in advanced OA. Meanwhile, IL-1β sup-
presses UGDH gene expression through activating SAP/
JNK and p38 MAPK pathways and subsequently modu-
lating the gene expression of UGDH’s trans-regulators
including Sp1, Sp3 and c-Krox. Accordingly, we specu-
late that IL-1β might be involved in the suppression of
UGDH gene expression in OA, which would probably
contribute to the OA pathogenesis.
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